IL284218B1 - Crystalline forms of and salt of 1-methyl-5-(2'-methyl-[1,1'-piphenyl]-yl)-h1-benzo[d]3,2,1]triazole-7-carboxylic acid and pharmaceutical preparations thereof - Google Patents
Crystalline forms of and salt of 1-methyl-5-(2'-methyl-[1,1'-piphenyl]-yl)-h1-benzo[d]3,2,1]triazole-7-carboxylic acid and pharmaceutical preparations thereofInfo
- Publication number
- IL284218B1 IL284218B1 IL284218A IL28421821A IL284218B1 IL 284218 B1 IL284218 B1 IL 284218B1 IL 284218 A IL284218 A IL 284218A IL 28421821 A IL28421821 A IL 28421821A IL 284218 B1 IL284218 B1 IL 284218B1
- Authority
- IL
- Israel
- Prior art keywords
- compound
- pharmaceutical composition
- salt
- tris
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784083P | 2018-12-21 | 2018-12-21 | |
| US201962791571P | 2019-01-11 | 2019-01-11 | |
| US201962882712P | 2019-08-05 | 2019-08-05 | |
| PCT/US2019/067897 WO2020132471A1 (en) | 2018-12-21 | 2019-12-20 | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL284218A IL284218A (en) | 2021-08-31 |
| IL284218B1 true IL284218B1 (en) | 2026-01-01 |
Family
ID=69185721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284218A IL284218B1 (en) | 2018-12-21 | 2021-06-20 | Crystalline forms of and salt of 1-methyl-5-(2'-methyl-[1,1'-piphenyl]-yl)-h1-benzo[d]3,2,1]triazole-7-carboxylic acid and pharmaceutical preparations thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12297179B2 (enExample) |
| EP (1) | EP3898597A1 (enExample) |
| JP (3) | JP2022515239A (enExample) |
| KR (1) | KR20220035022A (enExample) |
| CN (1) | CN113508108B (enExample) |
| AU (1) | AU2019403396B2 (enExample) |
| BR (1) | BR112021012305A2 (enExample) |
| CA (1) | CA3124401A1 (enExample) |
| CL (1) | CL2021001640A1 (enExample) |
| CO (1) | CO2021009309A2 (enExample) |
| CR (1) | CR20210394A (enExample) |
| GE (2) | GEAP202415700A (enExample) |
| IL (1) | IL284218B1 (enExample) |
| JO (1) | JOP20210147A1 (enExample) |
| MA (1) | MA54541A (enExample) |
| MX (1) | MX2021007536A (enExample) |
| NI (1) | NI202100055A (enExample) |
| PE (2) | PE20212197A1 (enExample) |
| PH (1) | PH12021551495A1 (enExample) |
| SG (1) | SG11202106526UA (enExample) |
| TW (1) | TWI875727B (enExample) |
| UA (1) | UA130491C2 (enExample) |
| WO (1) | WO2020132471A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211462T1 (hr) | 2017-04-24 | 2021-12-24 | Aurigene Discovery Technologies Limited | Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze |
| TWI818954B (zh) | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| ES3063941T3 (en) * | 2020-08-27 | 2026-04-21 | Servier Lab | Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma |
| WO2025227007A1 (en) * | 2024-04-26 | 2025-10-30 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014128669A2 (en) * | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| WO2018197997A1 (en) * | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001024785A2 (en) | 1999-10-01 | 2001-04-12 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| JP2007015952A (ja) | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| EP2276763A1 (en) | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
| EP2230232A1 (en) | 2009-03-13 | 2010-09-22 | Almirall, S.A. | Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |
| EP2228367A1 (en) * | 2009-03-13 | 2010-09-15 | Almirall, S.A. | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| US9012464B2 (en) * | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9360932B1 (en) | 2012-08-29 | 2016-06-07 | Intellect Motion Llc. | Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture |
| CN103965133B (zh) * | 2013-01-31 | 2018-11-30 | 华东理工大学 | 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途 |
| JP6961879B2 (ja) | 2015-12-30 | 2021-11-05 | レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
| JOP20190094A1 (ar) | 2016-10-27 | 2019-04-25 | Broad Inst Inc | مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh) |
| TWI818954B (zh) * | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| CA3184024A1 (en) * | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| ES3063941T3 (en) * | 2020-08-27 | 2026-04-21 | Servier Lab | Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma |
-
2019
- 2019-12-20 JO JOP/2021/0147A patent/JOP20210147A1/ar unknown
- 2019-12-20 US US17/416,910 patent/US12297179B2/en active Active
- 2019-12-20 UA UAA202104251A patent/UA130491C2/uk unknown
- 2019-12-20 AU AU2019403396A patent/AU2019403396B2/en active Active
- 2019-12-20 PE PE2021001052A patent/PE20212197A1/es unknown
- 2019-12-20 EP EP19839747.3A patent/EP3898597A1/en active Pending
- 2019-12-20 GE GEAP202415700A patent/GEAP202415700A/en unknown
- 2019-12-20 CN CN201980091991.XA patent/CN113508108B/zh active Active
- 2019-12-20 WO PCT/US2019/067897 patent/WO2020132471A1/en not_active Ceased
- 2019-12-20 TW TW108147117A patent/TWI875727B/zh active
- 2019-12-20 KR KR1020217022945A patent/KR20220035022A/ko not_active Ceased
- 2019-12-20 GE GEAP201915700A patent/GEP20247683B/en unknown
- 2019-12-20 BR BR112021012305-9A patent/BR112021012305A2/pt unknown
- 2019-12-20 PE PE2025003120A patent/PE20260309A1/es unknown
- 2019-12-20 CR CR20210394A patent/CR20210394A/es unknown
- 2019-12-20 JP JP2021536323A patent/JP2022515239A/ja active Pending
- 2019-12-20 MA MA054541A patent/MA54541A/fr unknown
- 2019-12-20 MX MX2021007536A patent/MX2021007536A/es unknown
- 2019-12-20 CA CA3124401A patent/CA3124401A1/en active Pending
- 2019-12-20 SG SG11202106526UA patent/SG11202106526UA/en unknown
-
2020
- 2020-01-09 PH PH1/2021/551495A patent/PH12021551495A1/en unknown
-
2021
- 2021-06-18 CL CL2021001640A patent/CL2021001640A1/es unknown
- 2021-06-20 IL IL284218A patent/IL284218B1/en unknown
- 2021-06-21 NI NI202100055A patent/NI202100055A/es unknown
- 2021-07-15 CO CONC2021/0009309A patent/CO2021009309A2/es unknown
-
2024
- 2024-08-07 JP JP2024131002A patent/JP7749080B2/ja active Active
-
2025
- 2025-05-07 US US19/201,581 patent/US20250270175A1/en active Pending
- 2025-09-22 JP JP2025156833A patent/JP2026001058A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014128669A2 (en) * | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
| WO2018197997A1 (en) * | 2017-04-24 | 2018-11-01 | Aurigene Discovery Technologies Limited | Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| BRITTAIN, HARRY G, POLYMORPHISM IN PHARMACEUTICAL SOLIDS., 31 December 2009 (2009-12-31) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250270175A1 (en) | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof | |
| EP3702351B1 (en) | Formulation comprising a mek inhibitor | |
| US11951100B2 (en) | Formulations of RBP4 inhibitors and methods of use | |
| TW201144297A (en) | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof | |
| EP2582689A1 (en) | New polymorphic form of imatinib base and preparation of salts thereof | |
| CN113968843A (zh) | 一种环己烷甲酰胺的新晶型及其制备方法 | |
| WO2007059500A2 (en) | Novel process and formulations | |
| KR20260007293A (ko) | 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법 | |
| CN114163453B (zh) | 一种洛普替尼晶型及其制备方法 | |
| CA3018610A1 (en) | Crystalline forms of hydrochloride of drug for treating or preventing jak-associated disease and preparation method thereof | |
| WO2021213380A1 (zh) | 吡嗪取代的烟酰胺的固体形式及其制备和用途 | |
| OA20637A (en) | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof. | |
| CA2990747A1 (en) | Phenyl amino pyrimidine compound or polymorph of salt thereof | |
| EA045339B1 (ru) | Кристаллические и солевые формы органического соединения и их фармацевтические композиции | |
| WO2011027988A2 (en) | Novel polymorphic form of prasugrel-hydrogen sulfate | |
| AU2020378025A1 (en) | Crystal form of Aprocitentan, preparation method therefor and use thereof | |
| US10793554B2 (en) | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone | |
| KR101872726B1 (ko) | 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물 | |
| WO2026040323A1 (zh) | 一种依鲁替尼单月桂醇硫酸盐、制备方法、应用 | |
| CN121941687A (zh) | 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途 | |
| WO2018130226A1 (zh) | 利奥西呱的新晶型及其制备方法和用途 | |
| CN108383799A (zh) | 抗肿瘤新药的合成方法及其药用盐和固体制剂 |